AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. The company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). It is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. In Mexico the company relies on manufacturing capabilities and a staff of 150 people.
Contact details
AstraZeneca S.A. de C.V.
Periférico Sur No. 4305, 5to piso
Col. Jardines de la Montaña, Del. Tlalpan
CP 14210 México DF
MEXICO
Tel: +52 (55) 5374 9600
Website: www.astrazeneca.com/mexico
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Consuelo Albarrán, co-founder and CEO of DEFI Latina Healthcare, showcases the increasing added value brought by this leading Cofepris-authorized third party (ATP) to the pharmaceutical industry, the recent expansion of…
Rodrigo Puga, the recently appointed general manager of Pfizer Mexico, documents his strategic priorities to further strengthen the company’s performance in Mexico and consolidate Pfizer’s leadership within the Mexican market…
General Manager of Merck Mexico, Pedro Galvis, showcases the strategic importance of the Mexican affiliate within Merck’s global network and explains the importance of public-private partnerships in enhancing patient access and…
Paulina Escobedo, general manager of B. Braun Medical Mexico, provides insights into the impressive development of this division since it was set up in the country in 2011, while the…
The university spin-off UDIBI continues its unstoppable ascension: after being recently recognized by Cofepris, Mexico’s sanitary agency, as an authorized laboratory to assess biotech treatments entering the Mexican market, UDIBI…
Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims…
The General Directors of Rayere explain how the historical Mexican pharma company has been leveraging its outstanding manufacturing capacity and product development expertise to become a thriving and reputed player…
Carlos Abelleyra Cordero, CEO Spanish Latin America of Aspen Labs, describes the rapid development of Aspen’s operational capacity throughout the region, in line with the company’s ambition to ultimately establish…
Karel Fucikovsky, general director PFM Latin America at Pierre Fabre, on the strategic focus of the company on operational and commercial excellence in Mexico and Latin America, which both stand as…
In an exclusive interview, Dr. José Narro Robles, Secretary of Health of Mexico, provides insight into the main challenges of the domestic healthcare system and his strategic priorities to improve…
Takeda Mexico’s José Manuel Caamaño discusses Takeda’s impressive growth prospects in Mexico, patient-centricity, the reopening of their cutting-edge manufacturing plant in Naucalpan, and his vision to transform Takeda into one…
José Reyes Baeza Terrazas, general director of ISSSTE (Institute for Social Security and Services for State Workers) documents some of the institution’s key specificities that make it one of the…
See our Cookie Privacy Policy Here